| Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00097214) | Eli Lilly and Company | 2004-11-01 |
| Effects of Teriparatide in Postmenopausal Women With Osteoporosis (NCT00079924) | Eli Lilly and Company | 2004-11-01 |
| Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection (NCT00547183) | Eli Lilly and Company | 2004-10-01 |
| A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer (NCT00102219) | Eli Lilly and Company | 2004-10-01 |
| A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder (NCT00191061) | Eli Lilly and Company | 2004-10-01 |
| An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (NCT00191516) | Eli Lilly and Company | 2004-10-01 |
| A Study in the Treatment of Acute Mania (NCT00767715) | Eli Lilly and Company | 2004-10-01 |
| Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems (NCT00547625) | Eli Lilly and Company | 2004-10-01 |
| Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode (NCT00191997) | Eli Lilly and Company | 2004-10-01 |
| Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy (NCT00083720) | Eli Lilly and Company | 2004-10-01 |
| A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder (NCT00122850) | Eli Lilly and Company | 2004-10-01 |
| Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes (NCT00192101) | Eli Lilly and Company | 2004-10-01 |
| To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC) (NCT00191191) | Eli Lilly and Company | 2004-10-01 |
| Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder (NCT00094549) | Eli Lilly and Company | 2004-10-01 |
| An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). (NCT00192023) | Eli Lilly and Company | 2004-10-01 |
| An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder (NCT00191737) | Eli Lilly and Company | 2004-10-01 |
| A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer (NCT00191347) | Eli Lilly and Company | 2004-10-01 |
| Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (NCT00422578) | Eli Lilly and Company | 2004-10-01 |
| Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months) (NCT00190736) | Eli Lilly and Company | 2004-09-01 |
| Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study (NCT00191724) | Eli Lilly and Company | 2004-09-01 |
| A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) (NCT00190775) | Eli Lilly and Company | 2004-09-01 |
| Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury (NCT00421083) | Eli Lilly and Company | 2004-09-01 |
| A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer (NCT00461786) | Eli Lilly and Company | 2004-09-01 |
| Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania (NCT00190892) | Eli Lilly and Company | 2004-09-01 |
| Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS) (NCT00479726) | Eli Lilly and Company | 2004-08-01 |
| Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (NCT00088465) | Eli Lilly and Company | 2004-08-01 |
| Duloxetine vs Placebo in the Treatment of General Anxiety (NCT00475969) | Eli Lilly and Company | 2004-08-01 |
| Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse (NCT00190957) | Eli Lilly and Company | 2004-08-01 |
| Switching to Duloxetine From Other Antidepressants (NCT00191932) | Eli Lilly and Company | 2004-08-01 |
| Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer (NCT00192036) | Eli Lilly and Company | 2004-08-01 |
| A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned (NCT00191750) | Eli Lilly and Company | 2004-07-01 |
| Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia (NCT00103571) | Eli Lilly and Company | 2004-07-01 |
| Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia (NCT00485901) | Eli Lilly and Company | 2004-07-01 |
| A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (NCT00087711) | Eli Lilly and Company | 2004-07-01 |
| A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer (NCT00192062) | Eli Lilly and Company | 2004-07-01 |
| Teriparatide Use in Hip Replaced Subjects (NCT00191321) | Eli Lilly and Company | 2004-07-01 |
| Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (NCT00386581) | Eli Lilly and Company | 2004-07-01 |
| Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder (NCT00090012) | Eli Lilly and Company | 2004-07-01 |
| Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia (NCT00088491) | Eli Lilly and Company | 2004-06-01 |
| Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents (NCT00191659) | Eli Lilly and Company | 2004-06-01 |
| Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion (NCT00190788) | Eli Lilly and Company | 2004-06-01 |
| A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer (NCT00191984) | Eli Lilly and Company | 2004-06-01 |
| Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection (NCT00547352) | Eli Lilly and Company | 2004-06-01 |
| Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD (NCT00485875) | Eli Lilly and Company | 2004-06-01 |
| Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia (NCT00088478) | Eli Lilly and Company | 2004-06-01 |
| Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia (NCT00485810) | Eli Lilly and Company | 2004-06-01 |
| Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer (NCT00088010) | Eli Lilly and Company | 2004-06-01 |
| Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder (NCT00122824) | Eli Lilly and Company | 2004-06-01 |
| Duloxetine in the Treatment of Melancholic Depression (NCT00191685) | Eli Lilly and Company | 2004-05-01 |
| Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder (NCT00191880) | Eli Lilly and Company | 2004-05-01 |
| A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma (NCT00192088) | Eli Lilly and Company | 2004-05-01 |
| Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response (NCT00191399) | Eli Lilly and Company | 2004-05-01 |
| Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes (NCT00110370) | Eli Lilly and Company | 2004-04-01 |
| Effects of Arzoxifene on Bone Mass and the Uterus (NCT00085956) | Eli Lilly and Company | 2004-04-01 |
| A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer (NCT00191451) | Eli Lilly and Company | 2004-04-01 |
| Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection (NCT00547495) | Eli Lilly and Company | 2004-03-01 |
| A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer (NCT00190710) | Eli Lilly and Company | 2004-03-01 |
| Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer. (NCT00191620) | Eli Lilly and Company | 2004-03-01 |
| Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer (NCT00320515) | Eli Lilly and Company | 2004-03-01 |
| Olanzapine in Patients With Borderline Personality Disorder (NCT00091650) | Eli Lilly and Company | 2004-03-01 |
| Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma (NCT00088205) | Eli Lilly and Company | 2004-03-01 |
| Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency (NCT00191165) | Eli Lilly and Company | 2004-03-01 |
| Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD (NCT00191035) | Eli Lilly and Company | 2004-03-01 |
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder (NCT00088036) | Eli Lilly and Company | 2004-02-01 |
| A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD (NCT00485849) | Eli Lilly and Company | 2004-02-01 |
| Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD (NCT00485459) | Eli Lilly and Company | 2004-02-01 |
| Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer (NCT00079872) | Eli Lilly and Company | 2004-02-01 |
| Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. (NCT00191711) | Eli Lilly and Company | 2004-02-01 |
| Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression (NCT00494377) | Eli Lilly and Company | 2004-02-01 |
| Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions. (NCT00190905) | Eli Lilly and Company | 2004-02-01 |
| Instillation of Gemcitabine in Patients With Superficial Bladder Cancer (NCT00191477) | Eli Lilly and Company | 2004-01-01 |
| 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen (NCT00191971) | Eli Lilly and Company | 2004-01-01 |
| Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy (NCT00485550) | Eli Lilly and Company | 2004-01-01 |
| Duloxetine Versus Paroxetine for Major Depression (NCT00489775) | Eli Lilly and Company | 2004-01-01 |
| Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD (NCT00191698) | Eli Lilly and Company | 2003-12-01 |
| A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer (NCT00078260) | Eli Lilly and Company | 2003-12-01 |
| A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer (NCT00192049) | Eli Lilly and Company | 2003-12-01 |
| Olanzapine Versus Comparator in the Treatment of Bipolar Disorder (NCT00485680) | Eli Lilly and Company | 2003-12-01 |
| Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT00071136) | Eli Lilly and Company | 2003-12-01 |
| A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer (NCT00191672) | Eli Lilly and Company | 2003-12-01 |
| New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery (NCT00074828) | Eli Lilly and Company | 2003-12-01 |
| An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer (NCT00207155) | Eli Lilly and Company | 2003-12-01 |
| Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes (NCT00191464) | Eli Lilly and Company | 2003-12-01 |
| Duloxetine Stress Urinary Incontinence Efficacy and Safety Study (NCT00475397) | Eli Lilly and Company | 2003-12-01 |
| Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD (NCT00486083) | Eli Lilly and Company | 2003-12-01 |
| A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg (NCT00382135) | Eli Lilly and Company | 2003-11-01 |
| Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression (NCT00073411) | Eli Lilly and Company | 2003-11-01 |
| Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis (NCT00532207) | Eli Lilly and Company | 2003-11-01 |
| Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer (NCT00490880) | Eli Lilly and Company | 2003-11-01 |
| Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression (NCT00485771) | Eli Lilly and Company | 2003-11-01 |
| A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder (NCT00190931) | Eli Lilly and Company | 2003-11-01 |
| Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease (NCT00191009) | Eli Lilly and Company | 2003-10-01 |
| A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction (NCT00381732) | Eli Lilly and Company | 2003-10-01 |
| Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia (NCT00088049) | Eli Lilly and Company | 2003-10-01 |
| Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder (NCT00190749) | Eli Lilly and Company | 2003-10-01 |
| Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic (NCT00490373) | Eli Lilly and Company | 2003-10-01 |
| Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD (NCT00191048) | Eli Lilly and Company | 2003-10-01 |
| Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection (NCT00547092) | Eli Lilly and Company | 2003-10-01 |
| Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma (NCT00190801) | Eli Lilly and Company | 2003-09-01 |
| A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer (NCT00190840) | Eli Lilly and Company | 2003-09-01 |